Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2731-2741

  Al Alwan, Laila A ^a   Chang, Ying ^a   Mogas, Andrea ^a   Halayko, Andrew J ^b   Baglole, Carolyn J ^a   Martin, James G ^a   Rousseau, Simon ^a   Eidelman, David H ^a   Hamid, Qutayba ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE;

AIRWAY SMOOTH MUSCLE CELL; ARTICLE; ASTHMA; CELL ACTIVATION; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

AIRWAY REMODELING; ASTHMA; BLOTTING, WESTERN; BRONCHI; CELL MOVEMENT; CHEMOKINE CXCL1; CHEMOKINE CXCL2; CHEMOKINES, CXC; FLOW CYTOMETRY; HUMANS; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, INTERLEUKIN-8A; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84883320616     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203421     Document Type: Article

References (74)

1. Ramos-Barbón, D., R. Fraga-Iriso, N. S. Brienza, C. Montero-Martínez, H. Verea-Hernando, R. Olivenstein, C. Lemiere, P. Ernst, Q. A. Hamid, and J. G. Martin. 2010. T cells localize with proliferating smooth muscle a-actin+ cell compartments in asthma. Am. J. Respir. Crit. Care Med. 182: 317-324.
2. Takeda, N., Y. Sumi, D. Préfontaine, J. Al Abri, N. Al Heialy, W. Al-Ramli, M. C. Michoud, J. G. Martin, and Q. Hamid. 2009. Epithelium-derived chemokines induce airway smooth muscle cell migration. Clin. Exp. Allergy 39: 1018-1026.
3. Kaur, D., R. Saunders, P. Berger, S. Siddiqui, L.Woodman, A.Wardlaw, P. Bradding, and C. E. Brightling. 2006. Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am. J. Respir. Crit. Care Med. 174: 1179-1188.
4. H17 cytokines induce human airway smooth muscle cell migration. J. Allergy Clin. Immunol. 127: 1046-1053.e2.
5. Parameswaran, K., K. Radford, A. Fanat, J. Stephen, C. Bonnans, B. D. Levy, L. J. Janssen, and P. G. Cox. 2007. Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. Am. J. Respir. Cell Mol. Biol. 37: 240-247.
6. Xu, W., W. Hong, Y. Shao, Y. Ning, Z. Cai, and Q. Li. 2011. Nogo-B regulates migration and contraction of airway smooth muscle cells by decreasing ARPC 2/3 and increasing MYL-9 expression. Respir. Res. 12: 14.
7. Al-Alwan, L. A., Y. Chang, C. J. Baglole, P. A. Risse, A. J. Halayko, J. G. Martin, D. H. Eidelman, and Q. Hamid. 2012. Autocrine-regulated airway smooth muscle cell migration is dependent on IL-17-induced growth-related oncogenes. J. Allergy Clin. Immunol. 130: 977-985.e6.
8. Olson, T. S., and K. Ley. 2002. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R7-R28.
9. Strieter, R. M., J. A. Belperio, M. D. Burdick, and M. P. Keane. 2005. CXC chemokines in angiogenesis relevant to chronic fibroproliferation. Curr. Drug Targets Inflamm. Allergy 4: 23-26.
10. Rudack, C., S. Maune, J. Eble, and J. M. Schroeder. 2003. The primary role in biologic activity of the neutrophil chemokines IL-8 and GRO-α in cultured nasal epithelial cells. J. Interferon Cytokine Res. 23: 113-123.
11. Doll, D., L. Keller, M. Maak, A. L. Boulesteix, J. R. Siewert, B. Holzmann, and K. P. Janssen. 2010. Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int. J. Colorectal Dis. 25: 573-581.
12. Zaja-Milatovic, S., and A. Richmond. 2008. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol. Histopathol. 23: 1399-1407.
13. Fitzpatrick, A. M., M. Higgins, F. Holguin, L. A. Brown, and W. G. Teague. 2010. The molecular phenotype of severe asthma in children. J. Allergy Clin. Immunol. 125: 851-857 (doi:10.1016/j.jaci.2010.01.048).
14. Goleva, E., P. J. Hauk, C. F. Hall, A. H. Liu, D. W. Riches, R. J. Martin, and D. Y. Leung. 2008. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J. Allergy Clin. Immunol. 122: 550-559.
15. Imaoka, H., N. Punia, A. Irshad, S. Ying, C. J. Corrigan, K. Howie, P. M. O'Byrne, G. M. Gauvreau, and R. Sehmi. 2011. Lung homing of endothelial progenitor cells in humans with asthma after allergen challenge. Am. J. Respir. Crit. Care Med. 184: 771-778.
16. Vandercappellen, J., J. Van Damme, and S. Struyf. 2008. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267: 226-244.
17. Ahuja, S. K., and P. M. Murphy. 1996. The CXC chemokines growth-regulated oncogene (GRO) α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271: 20545-20550.
18. Kramp, B. K., A. Sarabi, R. R. Koenen, and C. Weber. 2011. Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp. Cell Res. 317: 655-663.
19. Casadó, V., A. Cortés, J. Mallol, K. Pérez-Capote, S. Ferré,C. Lluis,R. Franco, and E. I. Canela. 2009. GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol. Ther. 124: 248-257.
20. Martínez Muñoz, L., P. Lucas, G. Navarro, A. I. Checa, R. Franco, C. Martínez-A, J. M. Rodríguez-Frade, and M. Mellado. 2009. Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers. J. Immunol. 183: 7337-7346.
21. Trettel, F., S. Di Bartolomeo, C. Lauro, M. Catalano, M. T. Ciotti, and C. Limatola. 2003. Ligand-independent CXCR2 dimerization. J. Biol. Chem. 278: 40980-40988.
22. Govindaraju, V., M. C. Michoud, M. Al-Chalabi, P. Ferraro, W. S. Powell, and J. G. Martin. 2006. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am. J. Physiol. Cell Physiol. 291: C957-C965.
23. Goncharova, E. A., D. A. Goncharov, and V. P. Krymskaya. 2006. Assays for in vitro monitoring of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cell migration. Nat. Protoc. 1: 2933-2939.
24. Suganuma, N., S. Ito, H. Aso, M. Kondo, M. Sato, M. Sokabe, and Y. Hasegawa. 2012. STIM1 regulates platelet-derived growth factor-induced migration and Ca2+ influx in human airway smooth muscle cells. PLoS ONE 7: e45056.
25. Joubert, P., S. Lajoie-Kadoch, I. Labonté, A. S. Gounni, K. Maghni, V. Wellemans, J. Chakir, M. Laviolette, Q. Hamid, and B. Lamkhioued. 2005. CCR3 expression and function in asthmatic airway smooth muscle cells. J. Immunol. 175: 2702-2708.
26. Kuma, Y., G. Sabio, J. Bain, N. Shpiro, R. Márquez, and A. Cuenda. 2005. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280: 19472-19479.
27. Pargellis, C., L. Tong, L. Churchill, P. F. Cirillo, T. Gilmore, A. G. Graham, P. M. Grob, E. R. Hickey, N. Moss, S. Pav, and J. Regan. 2002. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9: 268-272.
28. Mody, N., J. Leitch, C. Armstrong, J. Dixon, and P. Cohen. 2001. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502: 21-24.
29. Sebolt-Leopold, J. S., D. T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R. C. Gowan, H. Tecle, S. D. Barrett, A. Bridges, S. Przybranowski, et al. 1999. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5: 810-816.
30. Kojima, K., M. Shimanuki, M. Shikami, I. J. Samudio, V. Ruvolo, P. Corn, N. Hanaoka, M. Konopleva, M. Andreeff, and H. Nakakuma. 2008. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22: 1728-1736.
31. Gü rsel, D. B., Y. S. Connell-Albert, R. G. Tuskan, T. Anastassiadis, J. C. Walrath, J. J. Hawes, J. C. Amlin-Van Schaick, and K. M. Reilly. 2011. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential antiastrocytoma therapies. Neuro-oncol. 13: 610-621.
32. Hsieh, K. H., C. C. Chou, and B. L. Chiang. 1996. Immunotherapy suppresses the production of monocyte chemotactic and activating factor and augments the production of IL-8 in children with asthma. J. Allergy Clin. Immunol. 98: 580-587.
33. Luan, J., R. Shattuck-Brandt, H. Haghnegahdar, J. D. Owen, R. Strieter, M. Burdick, C. Nirodi, D. Beauchamp, K. N. Johnson, and A. Richmond. 1997. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 62: 588-597.
34. Maheshwari, A., R. D. Christensen, and D. A. Calhoun. 2003. ELR+ CXC chemokines in human milk. Cytokine 24: 91-102.
35. Antoniou, K. M., A. Tzouvelekis, M. G. Alexandrakis, K. Sfiridaki, I. Tsiligianni, G. Rachiotis, N. Tzanakis, D. Bouros, J. Milic-Emili, and N. M. Siafakas. 2006. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 130: 982-988.
36. Otto, G., M. Burdick, R. Strieter, and G. Godaly. 2005. Chemokine response to febrile urinary tract infection. Kidney Int. 68: 62-70.
37. Zhou, X., Q. Chen, J. Moore, J. K. Kolls, S. Halperin, and J.Wang. 2009. Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species. Infect. Immun. 77: 5059-5070.
38. Fekete, N., M. Gadelorge, D. Fürst, C. Maurer, J. Dausend, S. Fleury-Cappellesso, V. Mailänder, R. Lotfi, A. Ignatius, L. Sensebé, et al. 2012. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresisderived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14: 540-554.
39. Zhang, B. C., Z. W. Zhou, X. K. Li, and Y. W. Xu. 2011. PI-3K/AKT signal pathway modulates vascular smooth muscle cells migration under cyclic mechanical strain. Vasa 40: 109-116.
40. Esfandiarei, M., S. A. Yazdi, V. Gray, S. Dedhar, and C. van Breemen. 2010. Integrin-linked kinase functions as a downstream signal of platelet-derived growth factor to regulate actin polymerization and vascular smooth muscle cell migration. BMC Cell Biol. 11: 16.
41. Motobayashi, Y., Y. Izawa-Ishizawa, K. Ishizawa, S. Orino, K. Yamaguchi, K. Kawazoe, S. Hamano, K. Tsuchiya, S. Tomita, and T. Tamaki. 2009. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens. Res. 32: 188-193.
42. Jeffery, P. K. 1992. Pathology of asthma. Br. Med. Bull. 48: 23-39.
43. Greco, C. M., M. Camera, L. Facchinetti, M. Brambilla, S. Pellegrino, M. L. Gelmi, E. Tremoli, A. Corsini, and N. Ferri. 2012. Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. Cardiovasc. Res. 95: 366-374.
44. Parameswaran, K., G. Cox, K. Radford, L. J. Janssen, R. Sehmi, and P. M. O'Byrne. 2002. Cysteinyl leukotrienes promote human airway smooth muscle migration. Am. J. Respir. Crit. Care Med. 166: 738-742.
45. Phalitakul, S., M. Okada, Y. Hara, and H. Yamawaki. 2012. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 423: 844-849.
46. Wuyts, A., P. Proost, J. P. Lenaerts, A. Ben-Baruch, J. Van Damme, and J. M. Wang. 1998. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. Eur. J. Biochem. 255: 67-73.
47. Addison, C. L., T. O. Daniel, M. D. Burdick, H. Liu, J. E. Ehlert, Y. Y. Xue, L. Buechi, A. Walz, A. Richmond, and R. M. Strieter. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokineinduced angiogenic activity. J. Immunol. 165: 5269-5277.
48. Maudsley, S., S. A. Patel, S. S. Park, L. M. Luttrell, and B. Martin. 2012. Functional signaling biases in G protein-coupled receptors: game theory and receptor dynamics. Mini Rev. Med. Chem. 12: 831-840.
49. Goupil, E., S. A. Laporte, and T. E. Hébert. 2012. Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations. Mini Rev. Med. Chem. 12: 817-830.
50. González-Maeso, J., and S. C. Sealfon. 2012. Functional selectivity in GPCR heterocomplexes. Mini Rev. Med. Chem. 12: 851-855.
51. Saunders, R., A. Sutcliffe, D. Kaur, S. Siddiqui, F. Hollins, A. Wardlaw, P. Bradding, and C. Brightling. 2009. Airway smooth muscle chemokine receptor expression and function in asthma. Clin. Exp. Allergy 39: 1684-1692.
52. An, S. S., B. Fabry, X. Trepat, N. Wang, and J. J. Fredberg. 2006. Do biophysical properties of the airway smooth muscle in culture predict airway hyperresponsiveness? Am. J. Respir. Cell Mol. Biol. 35: 55-64.
53. Burgess, J. K., J. H. Lee, Q. Ge, E. E. Ramsay, M. H. Poniris, J. Parmentier, M. Roth, P. R. Johnson, N. H. Hunt, J. L. Black, and A. J. Ammit. 2008. Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma. J. Cell. Physiol. 216: 673-679.
54. Lee, K. S., H. K. Lee, J. S. Hayflick, Y. C. Lee, and K. D. Puri. 2006. Inhibition of phosphoinositide 3-kinased attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 20: 455-465.
55. Rossios, C., Y. To, G. Osoata, M. Ito, P. J. Barnes, and K. Ito. 2012. Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3- kinase inhibition. Br. J. Pharmacol. 167: 775-786.
56. Takeda, M., W. Ito, M. Tanabe, S. Ueki, H. Kato, J. Kihara, T. Tanigai, T. Chiba, K. Yamaguchi, H. Kayaba, et al. 2009. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase γ-deficient mice. J. Allergy Clin. Immunol. 123: 805-812.
57. Vadas, O., J. E. Burke, X. Zhang, A. Berndt, and R. L. Williams. 2011. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 4: re2.
58. Krymskaya, V. P., E. A. Goncharova, A. J. Ammit, P. N. Lim, D. A. Goncharov, A. Eszterhas, and R. A. Panettieri, Jr. 2005. Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration. FASEB J. 19: 428-430.
59. Day, R. M., Y. H. Lee, A. M. Park, and Y. J. Suzuki. 2006. Retinoic acid inhibits airway smooth muscle cell migration. Am. J. Respir. Cell Mol. Biol. 34: 695-703.
60. Seo, J., H. S. Lee, S. Ryoo, J. H. Seo, B. S. Min, and J. H. Lee. 2011. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Eur. J. Pharmacol. 673: 56-64.
61. Gouëffic, Y., C. Guilluy, P. Guérin, P. Patra, P. Pacaud, and G. Loirand. 2006. Hyaluronan induces vascular smooth muscle cell migration through RHAMMmediated PI3K-dependent Rac activation. Cardiovasc. Res. 72: 339-348.
62. Willis, A. I., S. Fuse, X. J. Wang, E. Chen, G. P. Tuszynski, B. E. Sumpio, and V. Gahtan. 2000. Inhibition of phosphatidylinositol 3-kinase and protein kinase C attenuates extracellular matrix protein-induced vascular smooth muscle cell chemotaxis. J. Vasc. Surg. 31: 1160-1167.
63. Zhang, L. J., B. B. Tao, M. J. Wang, H. M. Jin, and Y. C. Zhu. 2012. PI3K p110a isoform-dependent Rho GTPase Rac1 activation mediates H2S-promoted endothelial cell migration via actin cytoskeleton reorganization. PLoS ONE 7: e44590.
64. Graupera, M., J. Guillermet-Guibert, L. C. Foukas, L. K. Phng, R. J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P. R. Cutillas, et al. 2008. Angiogenesis selectively requires the p110a isoform of PI3K to control endothelial cell migration. Nature 453: 662-666.
65. Taboubi, S., F. Garrouste, F. Parat, G. Pommier, E. Faure, S. Monferran, H. Kovacic, and M. Lehmann. 2010. Gq-coupled purinergic receptors inhibit insulin-like growth factor-I/phosphoinositide 3-kinase pathway-dependent keratinocyte migration. Mol. Biol. Cell 21: 946-955.
66. De Laurentiis, A., O. E. Pardo, A. Palamidessi, S. P. Jackson, S. M. Schoenwaelder, E. Reichmann, G. Scita, and A. Arcaro. 2011. The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration. Cell. Signal. 23: 529-541.
67. Niedermeier, M., B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger. 2009. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113: 5549-5557.
68. Guerreiro, A. S., S. Fattet, B. Fischer, T. Shalaby, S. P. Jackson, S. M. Schoenwaelder, M. A. Grotzer, O. Delattre, and A. Arcaro. 2008. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin. Cancer Res. 14: 6761-6769.
69. Meng, Q., C. Xia, J. Fang, Y. Rojanasakul, and B. H. Jiang. 2006. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 18: 2262-2271.
70. Chen, C. H., J. M. Lai, T. Y. Chou, C. Y. Chen, L. J. Su, Y. C. Lee, T. S. Cheng, Y. R. Hong, C. K. Chou, J. Whang-Peng, et al. 2009. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS ONE 4: e5052.
71. Knight, Z. A., B. Gonzalez, M. E. Feldman, E. R. Zunder, D. D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, et al. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747.
72. Workman, P., P. A. Clarke, F. I. Raynaud, and R. L. van Montfort. 2010. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 70: 2146-2157.
73. Raynaud, F. I., S. Eccles, P. A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, et al. 2007. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67: 5840-5850.
74. Cain, R. J., B. Vanhaesebroeck, and A. J. Ridley. 2012. Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. Int. J. Biochem. Cell Biol. 44: 1929-1936.